Web Exclusives

First-line treatment with the high-affinity, highly potent PD-1 inhibitor cemiplimab-rwlc (Libtayo) significantly improved overall survival (OS) and progression-free survival (PFS) compared with standard platinum-based chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) and PD ligand 1 (PD-L1) expression on at least 50% of tumor cells. The results of the second preplanned interim analysis of the phase 3 EMPOWER-Lung 1 clinical trial were presented at the 2020 virtual meeting of the European Society for Medical Oncology (ESMO). Read Article ›

BRAF/MEK-targeted therapy rechallenge in patients with BRAF-mutation–positive advanced melanoma whose disease progress on first-line BRAF-targeted therapy and second-line immunotherapy leads to responses in approximately one-fourth of patients. Read Article ›

The latest analysis of the phase 3 EORTC 1325/KEYNOTE-054 clinical trial showed pembrolizumab to be superior to placebo after more than 3.5 years of follow-up on the end points of distant metastasis-free survival and relapse-free survival in patients with resected stage III melanoma. Read Article ›

In an analysis of a French melanoma database, 43% of patients treated with anti–PD-1 therapy experienced a late-onset immune-related adverse event, defined as an event occurring after ≥2 years of treatment. Read Article ›

Nivolumab continues to be an effective adjuvant treatment for patients with resected high-risk melanoma at 4 years, with sustained recurrence-free and distant metastasis-free survival benefit compared with ipilimumab. Read Article ›

Analysis of the randomized COMBI-AD trial at 5 years shows >50% relapse-free survival in patients with resected stage III BRAF V⁶⁰⁰-mutation–positive melanoma who received adjuvant treatment with the combination of dabrafenib plus trametinib. Read Article ›

In response to the COVID-19 pandemic, CMS has added coverage of telehealth services as part of a push by the agency to accelerate the use of telehealth by removing reimbursement barriers. Read Article ›

The international phase 3 INOVATYON clinical trial did not meet its primary end point of an improvement in overall survival with trabectedin added to pegylated liposomal doxorubicin (PLD) followed by platinum at progression compared with carboplatin plus PLD in patients with recurrent ovarian cancer. Trabectedin plus PLD may still have a role in patients with multiple previous lines of platinum. Read Article ›

In the treatment of patients with platinum-sensitive, recurrent ovarian cancer, a lower starting dose of niraparib in patients with a low body weight (77 kg) or low platelet count (150,000/μL) had similar efficacy as the fixed 300-mg starting dose versus placebo on the end point of progression-free survival, confirming a previous observation. Read Article ›

A review of the National Cancer Database reveals that use of neoadjuvant chemotherapy for advanced epithelial ovarian cancer increased markedly between 2004 and 2016. At the same time, median survival improved by more than 6 months. Study authors found no association between the 2 trends. Read Article ›

Data from a real-world setting show that a platinum-free interval >12 months was associated with the best outcomes after progression on PARP inhibitor maintenance in patients with high-grade serous ovarian cancer. Read Article ›

Genetic testing can play an important role in determining a patient’s risk for developing certain cancers and can be used to individualize treatment for better clinical outcomes. In a recent study published online in JAMA Oncology, researchers reported that universal multigene panel testing among patients with solid tumors was associated with increased detection of mutations compared with targeted testing based on standard guidelines. Read Article ›